Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfection

Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfection

Bibliographic Details
Main Authors:	Jin-Jin Chen, Li-Bo Li, Hong-Hong Peng, Shen Tian, Bin Ji, Chao Shi, Cheng Qian, Wen-Guo Jiang, Mei-Chen Liu, Ting-Ting Li, Yuan Shen, Li-Qun Fang, Guo-Lin Wang
Format:	Article
Language:	English
Published:	Elsevier 2023-04-01
Series:	The Lancet Regional Health. Western Pacific
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666606523000779

Similar Items

Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges
by: Thirumalaisamy P. Velavan, et al.
Published: (2023-03-01)

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
by: Jingyun Yang, et al.
Published: (2023-06-01)

XBB.1.5: A new threatening SARS-CoV-2 Omicron subvariant
by: Md. Aminul Islam, et al.
Published: (2023-04-01)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
by: Danyi Ao, et al.
Published: (2023-04-01)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
by: Rachael Pung, et al.
Published: (2023-08-01)

Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters
by: Peter J. Halfmann, et al.
Published: (2024-03-01)

Possible threat of the Omicron subvariants XBB.1.5 and BF.7 to the Indian subcontinent: A correspondence
by: Shankhaneel Ghosh, et al.
Published: (2023-03-01)

An omicron-specific neutralizing antibody test predicts neutralizing activity against XBB 1.5
by: Stephen Varvel, et al.
Published: (2024-01-01)

Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
by: Masaud Shah, et al.
Published: (2023-09-01)

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
by: Rajesh M. Valanparambil, et al.
Published: (2023-11-01)

XBB.1.16 Omicron subvariant rise to a variant of interest: Implications for global alertness and preparedness
by: Okesanya Olalekan John, B'MLS, et al.
Published: (2023-12-01)

A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2
by: Cai He, et al.
Published: (2023-06-01)

Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3
by: Julia N. Faraone, et al.
Published: (2023-12-01)

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
by: Andrei A. Pochtovyi, et al.
Published: (2023-09-01)

Continued evasion of neutralizing antibody response by Omicron XBB.1.16
by: Julia N. Faraone, et al.
Published: (2023-10-01)

Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination
by: Bin Ju, et al.
Published: (2023-06-01)

Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants
by: Tomokazu Tamura, et al.
Published: (2023-05-01)

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2
by: Airu Zhu, et al.
Published: (2023-03-01)

A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2
by: Syamala Rani Thimmiraju, et al.
Published: (2023-10-01)

Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster
by: Rafael Rahal Guaragna Machado, et al.
Published: (2024-01-01)

Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
by: Panke Qu, et al.
Published: (2023-05-01)

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
by: Masayuki Amano, et al.
Published: (2023-10-01)

Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant
by: Tomokazu Tamura, et al.
Published: (2024-02-01)

Transmission and re-infection of Omicron variant XBB.1.5 in hamstersResearch in context
by: Peter J. Halfmann, et al.
Published: (2023-07-01)

Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
by: Hui Zhao, et al.
Published: (2024-01-01)

Counterfactual analysis of the 2023 Omicron XBB wave in China
by: Hengcong Liu, et al.
Published: (2024-03-01)

XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants
by: Nita Patel, et al.
Published: (2023-11-01)

Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
by: Ka-Li Zhu, et al.
Published: (2023-02-01)

Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China
by: Xun Wang, et al.
Published: (2023-06-01)

Dynamic immune landscape in vaccinated-BA.5-XBB.1.9.1 reinfections revealed a 5-month protection-duration against XBB infection and a shift in immune imprintingResearch in context
by: Tingting Cui, et al.
Published: (2024-01-01)

XBB.1.5 emerges in the Americas: what it means to the region
by: Peter Hotez
Published: (2023-02-01)

Efficacy of small molecules against the severe acute respiratory syndrome coronavirus 2 XBB1.16 and XBB1.9.2.1
by: Lunzhi Yuan, et al.
Published: (2024-03-01)

Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1
by: Shuo Liu, et al.
Published: (2023-12-01)

An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB.1.5 and other mutants
by: Zongming Liu, et al.
Published: (2023-12-01)

The emergence of the Omicron XBB.1.5 variant in India: a brief report on clinical presentation of a few cases
by: Jasmine Samal, et al.
Published: (2023-06-01)

The Omicron XBB.1 Variant and Its Descendants: Genomic Mutations, Rapid Dissemination and Notable Characteristics
by: Raffaele Giancotti, et al.
Published: (2024-02-01)

Distinctive Features of the XBB.1.5 and XBB.1.16 Spike Protein Receptor-Binding Domains and Their Roles in Conformational Changes and Angiotensin-Converting Enzyme 2 Binding
by: Tej Sharma, et al.
Published: (2023-08-01)

Impact of SARS-CoV-2 envelope protein mutations on the pathogenicity of Omicron XBB
by: Yi Wang, et al.
Published: (2023-07-01)

Twitter-Based Sentiment Analysis and Topic Modeling of Social Media Posts using Natural Language Processing, to Understand People’s Perspectives Regarding COVID-19 Omicron Subvariants XBB.1.5 and BF.7
by: S.V. Praveen, et al.
Published: (2023-03-01)

Integrative Genome-Based Survey of the SARS-CoV-2 Omicron XBB.1.16 Variant
by: Fabio Scarpa, et al.
Published: (2023-09-01)